







Mobilizing Domestic Resources for the HIV Workforce

Estimating investment needs

Catherine Cantelmo HRH2030 | Palladium

Diana Frymus USAID/Washington

Bryan Patenaude USAID/Washington


Vamsi Vasireddy Office of the Global AIDS Coordinator





www.hrh2030program.org

HRH2030 strives to build the accessible, available, acceptable, and high-quality health workforce needed to improve health outcomes.





GHE

Health Workforce- A Cost Driver of Health and HIV Programs

HRH

Other

PEPFAR

Sources: I Hernandez-Pena et al, Bull WHO, 2013. P 2 PEPFAR ratios are not representative of actual data, but aim to illustrate the significance of the investment



The need for greater estimation of HRH financing requirements for HIV

- Sufficient financing of the HIV workforce is not only critical to achieving 95-95-95 targets but also maintaining achievements
- Greater analysis of the required resources is key for:
 - ✓ Making best use of available resources
 - Ensuring HIV HRH requirements incorporated into health workforce planning and mobilization of domestic resources
 - Sustainability of investments and guided transitions of donor-supported workers to domestic funding sources





Objectives

- I. Discuss how to generate evidence of HIV workforce needs and costs
- I. Discuss how to use this evidence to advocate for strategic investment and mobilization of resources in HRH for HIV



Catherine Cantelmo HRH2030 | Palladium

Estimating HIV Workforce Needs and Costs at the National or Subnational Level





Presentation overview


- Discuss why and how to estimate HIV workforce needs and costs at national or subnational levels
- Share examples from an assessment conducted in Uganda that involved answering the following questions:
 - **Baseline analysis** What are the current HIV HRH funding levels?
 - Fiscal space and cost scenario analysis How much funding may be available for HIV HRH from 2016 to 2020, and is this sufficient to meet national HIV targets? What is the potential funding gap under different service delivery models?
 - Political economy analysis (PEA) What are some of the political and structural barriers and enablers to the government increasing funding for HIV HRH?

Link to reports: <u>https://www.hrh2030program.org/investmentcaseuganda/</u>



Why estimate HIV workforce costs at national or subnational levels?

- Need to understand the big picture often assessments are done for specific facilities
- Critical evidence for investment cases and other domestic resource mobilization efforts
- Benefits of separating out HIV workforce needs and costs:
 - Many countries still have a high burden of HIV and have committed to ambitious targets
 - Need evidence to inform transition planning from external to domestic sources







Estimating HIV workforce costs

Who is bearing the cost of HRH for HIV?

Which cadres should be included in the analysis?

Defining the scope


What types of costs (e.g., preservice training to retention) need to be examined?

What are some key factors that may influence cost variation?



How do you estimate HIV workforce costs at national and subnational levels?

Extrapolation from facility-based assessments



Cons:

- Difficult to estimate total from a sample
- Based on current utilization/demand

Full-time equivalent (FTE) approach



One FTE for HIV = A health worker working full-time on HIV

Total clinical minutes required by cadre X for HIV per year

Total FTEs required for HIV


Clinical minutes per staff in cadre X

Cons:

- Need to understand division of labor and workload for other conditions in order to know how many health workers are needed overall
- Need quality data to inform estimates




Methods: Estimating facility-based clinical HRH for HIV FTEs and costs





Methods: Estimating facility-based clinical HRH for HIV costs


PEPFAR



Can be based on 1) current utilization/demand, for HIV services 2) total need based on disease burden, or 3) country HIV targets




Assessment in Uganda: Assumed numbers reached based on national HIV targets



*VMMC target based on FY18 target staying constant to 2020. ART and PMTCT target based on ACP enrollment plan. HTC target based on HRH2030 calculations and will be verified by ACP before inclusion in final report.



Methods: Estimating facility-based clinical HRH for HIV costs





Based on service delivery standards from HIV and other clinical guidelines. Data sources for time spent per patient and by task include time-and-motion studies and health worker interviews.




Assessment in Uganda: Number of visits varies by scenario

Frequency of	Complex or New Patients	Stable patients	Children	Pregnant and Breastfeeding Women
Scenario I: Current model (2013 addendum ART + PMTCT guidelines)				
Clinical assessments	9/year	4/year	9/year	9/year
Drug refills	9/year	4/year	9/year	9/year
Lab monitoring	VL or CD4 – 1/year	VL or CD4 – I/year	VL or CD4 – I/year	VL or CD4 – I/year
Scenario 2: Increased efficiency (2016 New ART guidelines)				
Clinical assessments	6/year	2/year	6/year	4/year
Drug refills	6/year	4/year	6/year	4/year
Lab monitoring	VL – 1/year CD4 – 1/year	VL – I/year	VL – 1/year CD4 – 1/year	VL – 2/year

Both scenarios assume Uganda will meet same government targets in 2020, the same type of health worker and amount of time is spent with a patient per specific service, and that the same percentage of services will be delivered in the public sector.



Results: Number of facility-based FTEs needed to reach national HIV targets



Key takeaways:

- Additional facility-based HRH are needed to reach HIV targets, regardless of service delivery model
- Fewer additional facility-based HRH are needed for HIV service delivery under the differentiated care scenario compared with the current service delivery model scenario
- Biggest increase from 2015 to 2020 is for lab staff, regardless of scenario
- This is an underestimate of overall workforce needs due to exclusion of community, lay and management HRH



Estimating salary costs: Weighted average annual salaries by cadre and sector in Uganda

Weighted average annual salaries (2015, USD)

	Private for profit*	Private not for profit	Public
Doctors	\$8,867 (\$7,882-\$9,852)	\$6,092	\$4,730
Nurses/midwives	\$1,349 (\$1,216-\$1,482)	\$1,194	\$1,990
Clinical Officers	\$3,319 (\$2,945-\$3,694)	\$3,052	\$3,574
Laboratory staff	\$2,033 (\$1,893-\$2,173)	\$1,330	\$2,335
Pharmacy staff	\$4,415	\$3,500	\$3,494

*Low and high estimates for private for-profit sector based on sensitivity analysis.

Salary calculations for private sector include National Social Security Fund contribution by employers, which is assumed to be 10% of base salary. All data was provided in UGX - we assume 1 UGX= 0.00028 \$U.S. We assume real wages stay constant.




What about community-based health workers?

Example: Peer mothers

Considering 1,500 PMTCT patients will participate in a peer-mother led support group a year...



...and the workload of a peer mother...



Workloads of community-based health workers depend on:

- Distance travelled
- Size of support group
- Type of support or services provided






Assumptions for community-based health workers in Uganda

	Number of Patients Managed by One Health Worker Per Year			Percentage of Time Spent	Stipend Cost Per Patient
Cadre	ART	HTS	VMMC	on HIV	Per Year
CASA/Expert Client	250–300	250–300	N/A	100%	\$0.60-0.72
CCLAD Leader	60–100	60–100	N/A	100%	\$1.80-3.00
Mentor Mother	100–150	100–150	N/A	50%	\$0.75-1.13
Linkage Facilitators	400–500	400–500	200–250	100%	\$0.50-0.62
Drama Member	300–350	300–350	500–700	50%	\$0.06-0.08

Analysis assumes 70% of ART patients interact with an expert client, all stable patients interact with a CCLAD leader, all pregnant women test at the community level, all PMTCT patients interact with a mentor mother, all new patients diagnosed at the community-level and 25% to 75% of VMMC clients interact with a linkage facilitator, and all patients are exposed to drama members.



Projected HRH Salary/Stipend Costs for Providing HIV Services in Uganda







HIV HRH Funding Gap in Uganda(2020)

	HIV HRH Cost Scenarios		
HIV HRH financial	Scenario I: Current service	Scenario 2: Increased efficiency	
space scenarios	delivery models	(ART differentiated care model)	
Scenario I: Constant funding levels (all sources)	Facility-based HRH: \$2,827,296 gap Community-based HRH: \$2,877,424 gap	Facility-based HRH: \$1,167,494 gap Community-based HRH: \$2,877,424 gap	
Scenario 2: Increased	Facility-based HRH: \$987,667 gap	Facility-based HRH: \$672,135 surplus	
government funding	Community-based HRH: \$2,877,424 gap	Community-based HRH: \$2,877,424 gap	

- Community health workers face large funding gap
- Uganda may not reach its HIV goals unless HRH recruitment targets are met, efficiency gains are made through national roll-out of differentiated HIV treatment models of care, private sector health workforce is leveraged for HIV service delivery, and investments are made in the community health workforce.



Methodological challenges and solutions

Common challenge	Potential solution
Separating time spent on a specific health area versus others, particularly for staff that do not directly interact with patients	Triangulate multiple data sources (e.g., interviews, direct observation); develop assumptions based on resource intensity (e.g., volume of patients)
Lack of data on community-based, lay, and managerial staff	Primary data collection/use of expert opinion, sensitivity analysis
Lack of data on the private sector	Primary data collection/use of expert opinion, sensitivity analysis
Evolving service delivery models (e.g., differentiated care for HIV)	Generate scenarios that show potential efficiency gains across models of care





Key takeaways

- Analysis in Uganda is relevant to other countries that may face fiscal space and political will constraints to increasing investment in the HIV workforce
- To develop a comprehensive HIV workforce investment case, countries need to:
 - Generate evidence on the HIV workforce, especially estimates of the resource requirements to meet needs and targets
 - Bring together stakeholders, including civil society, development partners, and government, to identify priority areas for HRH investment and develop a unified funding task
 - Develop a comprehensive investment case document that crafts arguments for increased HRH investment for HIV
 - Use the investment case to conduct targeted, relevant budget advocacy during key windows in the budget cycle





Catherine Cantelmo HRH2030 | Palladium *Panelist*



Bryan Patenaude USAID/Washington *Panelist*



Vamsi Vasireddy Office of the Global AIDS Coordinator Panelist







Catherine Cantelmo HRH2030 | Palladium Panelist

Question I:

How does this methodology compare to other tools available to estimate health workforce needs and costs?





Bryan Patenaude USAID/Washington *Panelist*

Question 2:

How can this information be used to support long-term sustainability of PEPFAR-supported staff and transition to domestic resources (this goes beyond public sector)?





Vamsi Vasireddy Office of the Global AIDS Coordinator Panelist

Question 3:

What has been country experience in using evidence to advocate for more strategic investment in the health workforce, including for HIV?





Catherine Cantelmo HRH2030 | Palladium *Panelist*



Bryan Patenaude USAID/Washington *Panelist*



Vamsi Vasireddy Office of the Global AIDS Coordinator *Panelist*

Question 4:

What other pieces of evidence are needed to convince ministries of finance and other stakeholders to invest in the HIV workforce, including community-based health workers?



File View Help 🌐 🖝	_ □ ʰ ×
▼ Audio	5 <u></u>
Sound C	heck 📲 🤶
Computer audio	
- 🧹 🔵 Phone call	
🖉 MUTED	
Transmit (Plantronics Savi 7x	x-M) 🗸
×	
Receive (Plantronics Savi 7xx	(-M)
	,
Talking: Liz Davis	
▼ Questions	5
[Enter a question for staff]	
	Send
Webinar Housekeepi	
Webinar ID: 608-865-37	-
🛞 GoToWebina	ar
~	


Questions?





info@hrh2030program.org

www.hrh2030program.org



This webinar is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of cooperative agreement no. AID-OAA-A-15-00046 (2015-2020) in partnership with The U.S. President's Emergency Plan for AIDS Relief (PEPFAR). The contents are the responsibility of Chemonics International and do not necessarily reflect the views of PEPFAR, USAID, or the United States Government.